Halozyme (HALO) Insider Notice: 8,829 Shares to Be Sold on NASDAQ
Rhea-AI Filing Summary
Halozyme Therapeutics (HALO) notice reports a proposed sale of 8,829 shares of common stock through Morgan Stanley Smith Barney LLC on 09/02/2025 on the NASDAQ. The shares were originally acquired as Restricted Stock Units from the issuer on 04/30/2021. The filing shows an aggregate market value of $645,841.35 for the shares and lists 116,966,000 shares outstanding for the issuer. No other sales in the past three months are reported, and the filer affirms they are not aware of undisclosed material adverse information.
Positive
- Clear acquisition history: the shares were acquired as Restricted Stock Units on 04/30/2021
- Broker identified: sale to be handled by Morgan Stanley Smith Barney LLC on NASDAQ
- No recent sales reported in the past three months for the selling person
Negative
- Reduction in insider-held shares: proposed sale will reduce the seller's holdings by 8,829 shares
- No Rule 10b5-1 plan date provided in the remarks, so no documented pre-established trading plan is shown
Insights
TL;DR: Insider plans to sell 8,829 RSU-derived shares; transaction size is very small relative to total shares outstanding.
The filing documents a proposed sale of 8,829 common shares with an aggregate market value of $645,841.35, to be executed via Morgan Stanley Smith Barney on NASDAQ. These shares were acquired as restricted stock units on 04/30/2021 and no other sales by the person are reported in the past three months. Compared with the reported 116,966,000 shares outstanding, the proposed sale represents a de minimis percentage of the company stock, implying limited direct market impact.
TL;DR: The notice is a routine disclosure of an intended sale by a person holding RSUs; it includes the standard attestation about material information.
The form contains required elements: issuer identity, broker (Morgan Stanley Smith Barney LLC), class (common), amount (8,829), acquisition detail (RSUs on 04/30/2021), and the attestation that the seller is unaware of undisclosed material adverse information. No plan-adoption date or Rule 10b5-1 instruction is provided in the remarks section. Documentation appears to meet Rule 144 notice requirements for a proposed sale.